cd44 apc  (R&D Systems)

Journal: Cell Reports Medicine

Article Title: Valrubicin-loaded immunoliposomes targeting antigens on immunosuppressive cells to circumvent resistance to cancer immunotherapy

doi: 10.1016/j.xcrm.2026.102632

Figure Lengend Snippet: Val-ILs and αPD-1 affect the growth and spread of breast tumor cells 10 6 4T1 cells were transplanted through i.d. injection into the mammary gland of female BALB/c mice. When tumors reached 50 mm 3 , mice were i.v. injected with Val-ILs (10 12 NPs) and i.p. injected with αPD-1 (200 μg) on days 6, 9, and 12. Analyses were performed on day 15 (A–E). (A) Tumor growth volumes measured in vivo. (B) Image of tumors isolated ex vivo from the mammary gland of mice (two independent in vivo experiments). Val-ILs-Combo was efficient in reducing the tumor volumes, and the combination of Val-ILs-Combo and αPD-1 was even more efficient. Mice without breast tumors are identified with a black cross. (C) FC on TAM cells in the TME and macrophages in the spleen, to identify M1-like and M2-like phenotypes. (D) Images of mice measured with in vivo imaging system technology showing the detection of bioluminescent 4T1 cells in the mammary gland, following treatment with Val-ILs-Combo and/or αPD-1. (E) FC was used to detect metastatic CD44 + GFP + 4T1 cells spreading to distant organs following treatment. Examples of FC plots and a heatmap displaying the mean percentages. Undetected (ud) indicates the absence of detectable tumor 4T1 cells. (F) On day 30, tumor-free mice were rechallenged with a secondary injection of 10 6 4T1 cells into the contralateral mammary gland. Tumor growth was monitored to evaluate the establishment of a protective anti-tumor memory. The number of mice used per group is indicated on the figure, data are shown as means ± SD, and p values are compared to Val-ILs-IgG + αIgG or between the different groups and are calculated using one-way ANOVA with Tukey’s multiple comparisons test. See also .

Article Snippet: APC anti-Mouse CD44 (Clone REA664) , Miltenyi Biotec , Cat# 130-119-121; RRID: AB_2751628.

Techniques: Injection, In Vivo, Isolation, Ex Vivo, In Vivo Imaging

Journal: bioRxiv

Article Title: KDM5-driven transcriptional noise fuels plasticity-led awakening and relapse in paediatric cancer

doi: 10.1101/2025.10.13.682004

Figure Lengend Snippet: (A) Differential transcriptional noise (overdispersion) analysis between BRI and MES cells (left) or BRI and ADRN cells (right). Dots represent individual genes, dashed lines statistical thresholds and numbers percentage of all noisy genes in each cell state. (B) GSEA of BRI-specific noisy genes in (A). ( C) Representative flow cytometry plots of SK-N-SH cells treated for five days with DMSO, IdU or Cisplatin. Coloured boxes represent CD44 gating strategy and numbers represent the percentage of cells in that gate. (D) Representative flow cytometry histograms across conditions and timepoints (Iso, isotype; Cis, cisplatin). (E) Quantification of the percentage of ADRN (CD44low), BRI (CD44int) and MES (CD44high) cells during IdU or cisplatin treatment. (F) Wound healing assay in SK-N-SH treated with the noise inducer IdU or the plasticity inducer TGF-ß. Lines represent average wound area across two replicates and shaded area represents standard error (G) Representative images of patient-derived xenograft (PDX) before and after being treated ex vivo with IdU, TGF-ß or a combination of both. (H) Quantification of the area, roundness and number of fusions between PDX spheroids in (G). (I) Gene Set Enrichment Analysis (GSEA) of genes differentially expressed between spheroids treated with a combination of IdU+TGF-ß and any other treatment. (J) GSEA of public MES and ADRN signatures in the genes differentially expressed spheroids treated with a combination of IdU+TGF-ß and any other treatment. Stars represent statistical significance resulting from a two-way (E) or one-way (F, H) ANOVA test with Tukey’s HSD (‘****’ p <0.0001 ‘***’ p <0.001, ‘**’ p<0.01, ‘*’ p <0.05, ‘ns’ p >0.05’).

Article Snippet: For experiments not including KDM5-C70, cells were stained with 2μL of anti-CD44 APC/Fire 750 antibody (103062, BioLegend, USA) for 30 min at 4°C.

Techniques: Flow Cytometry, Wound Healing Assay, Derivative Assay, Ex Vivo